Inserm Transfert, your partner for value creation and technology transfer

Inserm Transfert, founded in 2000, is the private subsidiary of Inserm, specialized in life sciences technology transfer and collaborative research projects funding. It works under a Public Service Concession Agreement (CSP).

0

patent families*

0

number of contracts and licenses*

* For the year 2021

0

millions of euros invested in Proof of concept

0

projects detected*

Serving research

The company supports Inserm research units and researchers in the process undertaken to create value from their work. Its actions are part of the translational continuum, from basic and technological research to clinical development, with the aim of creating economic and societal value.

Are you a Researcher?

Protecting my results
Involving companies
Funding my project
Thinking about entrepreneurship

Are you a Company?

A response dedicated to your needs
Our strategic areas of innovation
An exceptional offer
Plan France Relance en

Are you an Investor?

Investors

News

06 Dec 2022

Félicitations à Valérie Crepel pour son prix de l'innovation ! @InsermTransfert est fier d'avoir accompagné Valérie… https://t.co/fP3KkdS5JL

06 Dec 2022

Grand Prix de l’Inserm pour Olivier Delattre, @Inserm, @institut_curie, pour ses travaux sur les cancers des enfant… https://t.co/Xr6T0lwGhO

06 Dec 2022

Cérémonie des #PrixInserm2022. « la preuve du travail scientifique rigoureux et des efforts collectifs » menés par… https://t.co/sVHasDAMFE

06 Dec 2022

@InsermTransfert félicite les Lauréats des #EtoilesDeLEurope 2022 et est fier d'avoir accompagné David Devos (proje… https://t.co/UiPQs20qAK

06 Dec 2022

RT @Inserm: C'est ce soir ! Ne manquez pas la cérémonie de révélation des lauréates et lauréats des #PrixInserm2022 à partir de 18h30. Sui…

06 Dec 2022

RT @HERAresearch: Quelles sont les avancées scientifiques ? Où en est la recherche sur les perturbateurs endocriniens? #perturbateursendoc…

23 Nov 2022

@I4IDCongress IMMUNOTHERAPIES & INNOVATIONS FOR INFECTIOUS DISEASES CONGRESS 2022 à Lyon. C'est parti pour aujourd… https://t.co/yrSsCImYmy

17 Nov 2022

Ce matin webinaire de sensibilisation à l'#entrepreneuriat et présentation du parcours pré-entrepreneurial d'… https://t.co/NrCvj2xwvg

16 Nov 2022

Sophie Prévost, Ingénieur Brevets, Mandataire Européen, est intervenue cet après-midi à la table ronde « J'ai une s… https://t.co/6ryKxgJT6y

15 Nov 2022

Amel Bensaid, juriste @InsermTransfert, est intervenue dans le Master 2 Droit de la Recherche et valorisation de l'… https://t.co/P3Vy0YFmEh

14 Nov 2022

Pascale Auge, Présidente du directoire d'@InsermTransfert interviendra dans le cadre du cyle Femmes et Santé d'… https://t.co/miAv2BT2Gr

10 Nov 2022

@InsermTransfert est partenaire du #deeptech Normandie qui se déroulera le mercredi 16 novembre 2022 à l'@insarouen… https://t.co/E4ZDwpqjBV

09 Nov 2022

@InsermTransfert participe aujourd'hui à la 5ème journée scientifique de #MSDAVENIR, fonds de soutien à la recherch… https://t.co/VMfEvku03j

03 Nov 2022

@InsermTransfert annonce la signature d'un accord de collaboration avec Janssen pour 3 ans de recherches conjointes… https://t.co/3EnO4zCLsb

27 Oct 2022

Bel article de @mypharma sur le partenariat entre @InsermTransfert et @Theranexus A lire sur : https://t.co/m0IovJjDMn

26 Oct 2022

Grégoire Serra, Business Development Manager, est présent lors du 6th Annual Gene Therapy for Rare Disorders Europe… https://t.co/oPjMBAHjph

24 Oct 2022

@InsermTransfert participe à #bioeurope2022, la grande réunion du monde des #biotechs, à #Leipzig en Allemagne du 2… https://t.co/6bmL1eYJ4G

21 Oct 2022

@InsermTransfert et @Theranexus ont signé une alliance stratégique visant à l’identification de cibles potentielles… https://t.co/XtC44RQFWI

20 Oct 2022

@InsermTransfert et @Theranexus annoncent la signature d’une alliance pour l’identification de cibles potentielles… https://t.co/Mlqh0qat4c

19 Oct 2022

@InsermTransfert adresse ses félicitations à Jean-Emmanuel Sarry du Centre de recherches en cancérologie de Toulous… https://t.co/B97jxjjunv

Collaborative projects

High-quality support for a research excellence.

RITA-MI 2

H2020

RITA-MI 2 will conduct a phase 2b randomised double-blind placebo-controlled CT to assess the impact of B cell depletion with the CD20 mAb rituximab on left ventricular dysfunction and cardiac ...

CBIG-SCREEN

H2020

CBIG-SCREEN aims to tackle inequality in cervical cancer screening (CCS) continuum. Though CCS programmes drastically reduce cervical cancer mortality, they remain largely inaccessible and ...

EHVA

H2020

 the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines.

...

EJP-RD

H2020

The European Joint Program on Rare Diseases brings over 130 institutions from 35 countries 27 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, ...

REMEDIA

H2020

The overall objective of the REMEDIA project is to determine how and to what extent the exposome affects the severity and morbidity of Chronic Obstructive Pulmonary Disease (COPD) and Cystic ...

CARDIATEAM

IMI

Diabetic patients are 2.5 times more likely to develop heart failure than people without diabetes. In many patients, the diabetes causes a type of heart dysfunction called cardiomyopathy, which is ...

ENSAT-HT

H2020

This project will develop and evaluate an omics-based stratified health promotion program for patients with endocrine forms of hypertension.

...

COSY

RHU

The aim of our project is to transform the outcome and the medical care of patients with overgrowth syndromes (OS)

...

EU-TRAIN

H2020

"End stage renal diseases affect more than 3,900,000 patients worldwide with approximately 6% growth rate in 2016. Kidney transplantation is currently the best therapeutic option with around ...

KTD INNOV

RHU

"KTD-Innov combines molecular medicine (MM) and health information technology (HIT) to deliver a precision immune monitoring and diagnosis system applied in kidney transplantation: the Integrative ...

HUGODECA

H2020

"The HUGODECA project is a European funded research initiative investigating how human gonads (either an ovary or a testis) develop in the embryo in order to understand how the initially ...

CARMMA

RHU

CARMMA is based on the hypothesis that obesity co-morbidities are associated with an early senescence of adipose tissue (AT). The main objective of CARMMA is to determine the common and central ...

iVASC

RHU

iVASC est un consortium de chercheurs, de cliniciens et d’industriels, qui vise à mettre au point de nouveaux outils de recherche dans le domaine de l’athérothrombose et à les appliquer à ...

CARE

IMI

The CARE consortium is a coalition of 37 academic institutions, pharmaceutical companies and non-profit research organizations whose main objectives are the development of therapeutics (i) to ...

TheraLymph

H2020

Lymphedema is a disabling condition of localised accumulation of fluid in a tissue caused by a compromised lymphatic system. It is an incurable disease that affects millions of people worldwide and...

AB-DiRecT

IMI

Developing antibacterials for resistant infections. An alarming rise globally in antibiotic-resistant infections and a search for new solutions is the motivational force behind project AB-DiRecT. ...

IP-CURE-B

H2020

To develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune...

VHFMoDRAD

IMI

VHFMoDRAD will develop and deliver rapid and point-of-care singel/multiplex diagnostic tool(s) that will significantly increase our capacity to handle outbreaks with Filoviruses and other viral ...

CCHFVaccine

H2020

The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) ...

ERINHA-Advance

H2020

One of the great challenges of the 21st century is to develop the capacity to prevent and react to outbreaks caused by highly pathogenic human and animal microorganisms, which are generally ...

EU-JAV

EU health programme

EU-JAV brings together the European Commission, health ministries, international policymakers and organisations, institutes, universities from 20 countries and a wide range of stakeholders, including ...

ZIKAlliance

H2020

ZIKAlliance is a multinational, multi-disciplinary research consortium comprised of 54 partners worldwide. It investigates clinical, fundamental, environmental and social aspects of ZIKV infection,...

EBOVAC2

IMI

" The main objective of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine....

R-LINK

H2020

The main objective of this study is to identify the eligibility criteria for treatment with lithium in bipolar I disorders (BDI) in terms of response, safety and tolerability. R-LiNK proposes a ...

QUID NASH

RHU

The main aim of the QUID-NASH program is to develop a virtual liver biopsy (non invasive) for the diagnosis and staging of NASH (Non Alcoholic SteatoHepatitis) in patients with type 2 diabetes,...

PREVAC-UP

The project PREVAC-UP is built around the PREVAC consortium. Its two primary objectives are to determine (i) the long-term immunogenicity and safety and (ii) durability of humoral and cellular ...

PREMSTEM

H2020

PREMSTEM aims to validate umbilical cord derived human mesenchymal stem cells as a regenerative therapy for encephalopathy of prematurity to improve the quality of life for preterm infants and ...

OBERON

H2020

The OBERON project will build an integrated approach for testing and assessment (IATA) to detect endocrine disruptors-related metabolic disorders by developing, improving and validating a battery of ...

MIROCALS

H2020

Efficacy and safety of low-dose IL2 (ld-IL2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients...

miniNO

H2020

The miniNO project will conduct out pioneering research on the connection between alterations in minipuberty and infantile nitric oxide (NO) signaling in the brain, and comorbidities that appear ...

MEDIT-AGEING

H2020

As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimer’s disease, AD), sleep disturbances and depression, all ...

MAD-CoV 2

IMI

The overall aim of MAD-CoV 2 project is to develop and deliver a treatment for COVID-19 patients, which will significantly increase our capacity to handle the current outbreak of SARS-CoV-2. In ...

JPsustaiND

H2020

The overall aim of JPsustaiND is to support the development and extension of the capacities of the EU Joint Programming Initiative on Neurodegenerative Diseases, in particular Alzheimer's (JPND). ...

JPcofuND2

H2020

With the objective of promoting research aimed at changing the trajectory of these debilitating diseases, JPco-fuND 2 launched in January 2019, a joint transnational call supported by 27 countries for...

JPco-fuND

H2020

This initiative launched a joint transnational call for proposals, as a joint effort of 20 countries, aimed at supporting international research collaborations in three JPND priority areas: ...

HERA

H2020

HERA will set the priorities for an environment and health research agenda in the EU by adopting a holistic and systemic approach in the face of global environmental changes. Research will support ...

HBM4EU

H2020

HBM4EU is a joint effort of 30 countries, the European Environment Agency and the European Commission, co-funded under Horizon 2020. The initiative is coordinating and advancing human biomonitoring in...

FAIR-PARK-II

H2020

"FAIR PARK II will primarily investigate the effects of an iron chelation therapy on the progression of handicap in Parkinson's disease.
The project will run for five years (2015 - 2020) and ...

FAIR

H2020

The project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome antimicrobial resistance in pneumonia. The research focuses on the unique immunomodulator flagellin that ...

EU-RESPONSE

H2020

The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and ...

EBRA

H2020

EBRA aims at reducing the fragmentation and duplication of research efforts and at fostering synergies through enhanced coordination of brain research efforts at the EU and global level....